Appus, it is preclinical biological and potentially autologus cell therapy for autoimmune and chronic inflammatory dieses.
As a biological intervention in vitro, ex vivo (human PBMC) the increases of the IL-10 and decrease the TNF-alfa level was observed. At in vivo mouse model of collagen induced arthritis(CIA) Appus decreased the pathological score about 50% and delayed for 5 days the pathological symptoms development when used in therapeutic mode. Acute toxicity done on rats with a 50x over dosages do not disclose any histopathology and physiological differences among the experimental groups. The positive Appus activity was observed when was used as combinatorial therapy with antibiotics on the dog Pyometra disease.